Therapeutic AIBP expression contributes to synaptic preservation and vision restoration against glaucomatous neuroinflammation
- 1University of California San Diego
Abstract
Lowering intraocular pressure (IOP) is the only approved treatment for glaucoma, yet retinal ganglion cell (RGC) degeneration and vision loss often progress despite reducing IOP. Apolipoprotein A-I binding protein (AIBP) stabilizes ATP-binding cassette subfamily A member 1 (ABCA1) and promotes cholesterol efflux, thus controlling cholesterol-rich lipid rafts and restraining lipid raft-dependent Toll-like receptor 4 (TLR4) inflammatory signaling. Here we show that AAV2-mediated expression of human AIBP (hAIBP) preserves inner retinal synaptic integrity and visual function in experimental glaucoma without altering IOP. In DBA/2J mice, a single intravitreal injection of AAV2-hAIBP at 5 months protected RGCs and preserved pattern electroretinogram and pattern visual evoked potential responses at 10 months, even though IOP was indistinguishable from empty-vector controls. AAV2-hAIBP preserved CaMKII and synapsin phosphorylation, restored synaptophysin and PSD95 in the inner plexiform layer, and reduced the expression of TLR4, complement C1q, IBA1, IL-1b, and IL-6 induction in Muller glia and microglia. Comparable protection was observed in microbead-induced ocular hypertension in C57BL/6 mice, both when the AAV2-hAIBP was delivered before microbead injection and when it was delivered after IOP elevation was established. Elevated IOP reduced endogenous retinal AIBP and ABCA1 expression, and AAV2-hAIBP restored both. Protection required the TLR4-binding domain, as an AIBP mutant lacking this domain failed to preserve RGCs. Conversely, AIBP knockout retinas exhibited increased CaMKII phosphorylation and reduced synaptophysin in the absence of elevated IOP. These findings identify synaptic preservation through the AIBP-TLR4 axis as an IOP-independent therapeutic mechanism and support AAV2-hAIBP as a candidate gene therapy for glaucoma.
Related
- The cochlear macrophage in presbycusis: inflammaging, neuroinflammation, and targets for therapeutic modulation
- The cGAS-STING pathway in traumatic brain injury: mechanisms of neuroinflammation and therapeutic strategies
- Molecular Signatures of HIV-Induced Neuroinflammation and Neurodegeneration in Human Cerebral Organoids: Identification of Therapeutic Targets for NeuroHIV.
- The gasdermin family in depression-associated neuroinflammation: established evidence, emerging mechanisms, and therapeutic perspectives
- The Antigen-Presentation Bottleneck in Pediatric Solid Tumors: Developmental Antigens, MHC-I Suppression, and Therapeutic Restoration of Tumor Immune Recognition
BibTeX
@misc{bastola2026therapeutic,
title = {{Therapeutic AIBP expression contributes to synaptic preservation and vision restoration against glaucomatous neuroinflammation}},
author = {T. Bastola and S. Hwang and Z. Shen and S.-H. Choi and S. Choi and E. Jang and M. Poudel and K.-Y. Kim and Y. I. Miller and R. N. Weinreb and W.-K. Ju},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.10.758145},
url = {https://www.biorxiv.org/content/10.64898/2026.10.10.758145v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Therapeutic AIBP expression contributes to synaptic preservation and vision restoration against glaucomatous neuroinflammation
AU - T. Bastola
AU - S. Hwang
AU - Z. Shen
AU - S.-H. Choi
AU - S. Choi
AU - E. Jang
AU - M. Poudel
AU - K.-Y. Kim
AU - Y. I. Miller
AU - R. N. Weinreb
AU - W.-K. Ju
PY - 2026
DA - 2026/10/10
PB - bioRxiv
DO - 10.64898/2026.10.10.758145
UR - https://www.biorxiv.org/content/10.64898/2026.10.10.758145v1
AB - Lowering intraocular pressure (IOP) is the only approved treatment for glaucoma, yet retinal ganglion cell (RGC) degeneration and vision loss often progress despite reducing IOP. Apolipoprotein A-I binding protein (AIBP) stabilizes ATP-binding cassette subfamily A member 1 (ABCA1) and promotes cholesterol efflux, thus controlling cholesterol-rich lipid rafts and restraining lipid raft-dependent Toll-like receptor 4 (TLR4) inflammatory signaling. Here we show that AAV2-mediated expression of human AIBP (hAIBP) preserves inner retinal synaptic integrity and visual function in experimental glaucoma without altering IOP. In DBA/2J mice, a single intravitreal injection of AAV2-hAIBP at 5 months protected RGCs and preserved pattern electroretinogram and pattern visual evoked potential responses at 10 months, even though IOP was indistinguishable from empty-vector controls. AAV2-hAIBP preserved CaMKII and synapsin phosphorylation, restored synaptophysin and PSD95 in the inner plexiform layer, and reduced the expression of TLR4, complement C1q, IBA1, IL-1b, and IL-6 induction in Muller glia and microglia. Comparable protection was observed in microbead-induced ocular hypertension in C57BL/6 mice, both when the AAV2-hAIBP was delivered before microbead injection and when it was delivered after IOP elevation was established. Elevated IOP reduced endogenous retinal AIBP and ABCA1 expression, and AAV2-hAIBP restored both. Protection required the TLR4-binding domain, as an AIBP mutant lacking this domain failed to preserve RGCs. Conversely, AIBP knockout retinas exhibited increased CaMKII phosphorylation and reduced synaptophysin in the absence of elevated IOP. These findings identify synaptic preservation through the AIBP-TLR4 axis as an IOP-independent therapeutic mechanism and support AAV2-hAIBP as a candidate gene therapy for glaucoma.
ER -